A feasibility study of capecitabine plus oxaliplatin (CapeOX) and S-1 plus oxaliplatin (SOX) for unresectable advanced or reccurent gastric cancer

Trial Profile

A feasibility study of capecitabine plus oxaliplatin (CapeOX) and S-1 plus oxaliplatin (SOX) for unresectable advanced or reccurent gastric cancer

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2014

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Capecitabine; Oxaliplatin
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top